Funding Daily Summary
Funding Daily Summary: What Happened on November 14, 2026
Windward raises $225 million in IPO and Sanofi private placement
PhaSER received a renewed Gates Foundation grant, while Rezera postponed its planned offering.
Today in brief
Windward Bio Group raised $225 million through an IPO and a separate investment from Sanofi.12 The money will fund two respiratory and immunology programs, with data expected in 2027 and pivotal asthma results expected in 2029.23
Windward raises $225 million for two antibody programs
Windward priced about 10.3 million IPO shares at $17 each, raising $175 million, and secured another $50 million from Sanofi in a private placement.23 The offering was priced at the midpoint of its proposed range, and Windward shares rose 68% in after-hours trading Friday.12
The proceeds will mainly support WIN378, an antibody targeting TSLP that is being tested for severe asthma and chronic obstructive pulmonary disease, and WIN027, which blocks TSLP and IL-13.23 Windward expects asthma and COPD data for WIN378 and early results for WIN027 in 2027.23 The company expects preliminary results from two pivotal asthma studies in the first half of 2029 and estimates its cash will last into that period.23
Also worth knowing
Also published
- Windward Bio catches $175m from its IPO pharmaphorum
- Windward prices $175M IPO to advance China-licensed lung drugs BioPharma Dive